Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 16/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261688 | 0.93 | ADRB2 (0.56) | ADRB2ADRB3ADRB1CYP3A4CYP2D6 | |
| SCHEMBL4261685 | 0.93 | ADRB2 (0.56) | ADRB2ADRB3ADRB1CYP3A4CYP2D6 | |
| SCHEMBL4255084 | 0.88 | ADRB2 (0.57) | ADRB2ADRB3ADRB1CYP2D6 | |
| SCHEMBL4389552 | 0.86 | ADRB2 (0.54) | ADRB2ADRB3ADRB1CYP2D6 | |
| SCHEMBL4389556 | 0.86 | ADRB2 (0.54) | ADRB2ADRB3ADRB1CYP2D6 | |
| SCHEMBL4256482 | 0.86 | ADRB2 (0.67) | ADRB2ADRB3ADRB1GLA | |
| SCHEMBL4256662 | 0.85 | ADRB2 (0.40) | ADRB2ADRB3ADRB1GLACYP3A4 | |
| SCHEMBL13754627 | 0.84 | ADRB2 (0.39) | ADRB2ADRB3ADRB1GLA | |
| SCHEMBL10662496 | 0.84 | ADRB2 (0.52) | ADRB2ADRB3ADRB1GLACYP2D6 | |
| SCHEMBL10662416 | 0.84 | ADRB2 (0.52) | ADRB2ADRB3ADRB1GLACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1624868-B9 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2009-08-12 | — | — | EP | claimed |
| EP-1624868-B1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | claimed |
| EP-1624868-B9 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2009-08-12 | — | — | EP | disclosed |
| EP-1624868-B9 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2009-08-12 | — | — | EP | disclosed |
| EP-1624868-B1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| EP-1624868-B1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-7268147-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268147-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268147-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1624868-A1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL!PHENYL DERIVATIVES AS BETA2 AGONISTS | Pfizer Limited (GB) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004100950-A1 | ‘(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)-PROPYL!PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| US-20040229904-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229904-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B1, CYP11B2 | ADRB2 901/4885ADRB3 802/4885ADRB1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.